Valley Ready

Want to build a network in Silicon Valley? Looking to commercialize in the US?

Applications will be open for Fall 2026 cohort early next year!

About CELS Valley Ready

The CELS Valley Ready (VR) program is a curated, high-impact experience that connects scaling founders like you with U.S. investors, seasoned mentors, and sector-specific experts and champions, all while helping you sharpen your pitch, deepen your network, and build a roadmap for market success.

This isn’t a one-size-fits-all accelerator, it’s a curated growth experience built for high-potential companies ready to scale in the U.S.

What You’ll Gain

  • Dedicated Mentorship: One-on-one guidance from a senior industry mentor throughout the program.

  • Targeted Expert Support: Personalized introductions to domain experts and champions based on the cohort's areas of need (e.g., FDA, reimbursement, IP, fundraising).

  • Real-Time Feedback: Early pitch sessions with investors or mentors to help tailor your fundraising strategy.

  • Custom-Curated Content: GTM workshops and custom roundtables designed around your company’s specific challenges and growth stage.

  • Peer Learning Streams: Opportunities to connect with like-minded founders by subsector (therapeutics, diagnostics, devices).

  • In-Person Immersion: Two days in San Francisco,  that includes 1:1 investor meetings, workshops, and networking, including a ticket to our annual Charter Member dinner.

  • Annual Showcase: Each company receives one ticket to attend our annual Canada in the Valley Showcase. This includes two days of speakers, executive roundtables, 1:1 investor meetings and a networking reception. 

EXPLORE CELS THROUGH OUR INFO SESSION

Learn more about CELS, our Valley Ready program, and other ways to connect into Silicon Valley for capital and other strategic connections. View dates and RSVP below.

RSVP Here

Fall 2025 Participating Companies

Program Timeline & Workshops

  • - Program Kick-off

    - Founders Journey

    - Best Practices When Raising Capital from U.S. Investors

  • - Human Capital - how to elevate key executive roles, advisors and outsourcing or fractional roles

    - Corporate Strategy: How to build value in your company on a shoestring budget

    - How to incorporate AI into your executive toolbox

    - IP and Patent Consideration with US Expansion

  • - Setting up a business in the US

    - Understanding Cross Border Taxes

    - How to Effectively Manage Your Board

    - In-market 2-days of programming

    - Corporate Structure & U.S. Considerations

    - Growing Your Executive Presence

    - Wrap Up & Graduation

Apply Here

Participating Program Speakers Fall 2025

  • Leigh Hsu

    Leigh Hsu

    Chief Executive Officer

    Atticus Pharma

  • Zaneta Odrowaz

    Zaneta Odrowaz

    Chief Business Officer and Co-Founder

    Attovia Therapeutics

  • Angele Maki

    Chief Business Officer

    Hummingbird BioScience

  • Bodour Salhia

    Bodour Salhia

    Interim Chair

    Department of Cancer Biology Keck School of Medicine

  • Ashley Neville

    Ashley Neville

    Director of Insights

    Carta

  • Tamir Meiri

    Tamir Meiri

    Principal, Venture Investments

    Johnson & Johnson – JJDC

  • Helen Siaw

    Helen Siaw

    Senior Associate

    Aditum Bio

  • Michele Colucci

    Michele Colucci

    Founder and Managing Partner

    DigitalDx Ventures

  • David Sans

    David Sans

    Senior Managing Director of Healthcare

    D. Boral Capital

  • Cedric Bisson

    Partner

    Teralys Capital

Past Participating Program Speakers, Mentors & Investors

  • Michael Leung

    Michael Leung

    Co-founder & COO

    Spect Inc.

  • Ritish Patnaik

    Ritish Patnaik

    CEO and Co-Founder

    Curve Biosciences

  • Angele Maki

    Chief Business Officer

    Hummingbird BioScience

  • Alex Mok

    Alex Mok

    Founder/CEO

    Mantra Bio

  • Rami Hannoush

    Rami Hannoush

    Partner

    Versant Ventures

  • Scott St. Germain

    Vice President and Flu Business General Manager

    Genentech

  • Ali Samiaan

    Ali Samiaan

    Founder

    Poplar Access Advisors

  • Qing Zhang

    Qing Zhang

    Partner

    LDV Partners

  • Hicham Alaoui

    Hicham Alaoui

    Chief Scientific Officer

    Glycomine Inc.

  • Corey Zankowski

    Founder & CEO

    Amplifai Oncology

  • Mark Arundine

    Mark Arundine

    Business Development Head

    Genentech

  • JC Simbana

    JC Simbana

    Managing Director

    Customers Bank

  • Michael Maszy

    Michael Maszy

    Chair

    The Band of Angels

  • Shiva Amiri

    Shiva Amiri

    Partner, VP - Head of Data and AI

    Pivotal Life Sciences

  • Dongxue Wang

    Corporate venture investor/clinical researcher

    GUDU MEDICAL PTE.LTD/UCSF

  • Arnold Lee

    Arnold Lee

    General Partner

    Sugati Ventures

  • Gilly Regev

    Co-Founder, Director

    SaNOtize

  • Richard McDerby

    Richard McDerby

    Partner

    Manatt Ventures

  • Michel Narganes

    Partner

    Manatt Ventures

  • Hamid Farzaneh

    Partner

    Bridge 2

  • Bassam El-Fahmawi

    President & Chief Technical Officer

    Mawi DNA Technologies

  • Cedric Bisson

    Partner

    Teralys Capital

  • Qing

    Qing Zhang

    Partner

    LDV Partners

  • Seiya Takahashi

    Venture Partner

    Hike Ventures

  • Marlene Grenon

    Venture Partner

    IA Seed Ventures

  • David Schuster

    David Schuster

    Managing Partner

    UpScalerVC

  • Charline Kempter

    Trade Attaché

    Quebec Trade Office in Silicon Valley

  • Tom Vogelsong

    Startup Scout

    K2X Technology and Life Science

  • Alicia Chung

    Alicia Chung

    Venture Advisor

    Magnet Ventures

  • Mike Henry

    Mike Henry

    Chief Business Officer

    Aldatu Biosciences

  • Nicolas Saint-Arnaud

    Nicolas Saint-Arnaud

    Co-founder, Engineering Lead

    SURUDO

  • Soyoung Park

    Soyoung Park

    General Partner

    1004 Venture Partners

  • Ajit Singh

    Managing Director and General Partner

    Artiman Ventures

  • Alex Efron

    Healthcare & Life Sciences Investor

    Telegraph Hill Partners

  • Tom Vogelsong

    Angel Investor, Life Science & Tech Advisor

    K2X Capital

  • Gloria Maceiko

    Managing Director and Founder

    Silicon Valley Advantage

  • Cheryl Reicin

    Partner

    Mintz

  • Humphrey Polanen

    CEO and Board Chair

    Deep Medicine Acquisition Corp

  • Mark Mitchell

    Senior Director, R&D Finance

    Alexion Pharmaceuticals

  • Oguzhan Atay

    Co-founder & CEO

    BillionToOne

  • Tarek El-Sawy

    Venture Capital Partner

    Raiven Capital

Testimonials